Agency Information Collection Activities; Proposed Collection; Comment Request; Recordkeeping Requirements for Microbiological Testing and Corrective Measures for Bottled Water, 25752-25753 [E9-12493]
Download as PDF
25752
Federal Register / Vol. 74, No. 102 / Friday, May 29, 2009 / Notices
DATES: The meeting will take place
Thursday, June 25, 2009, from 9 a.m. to
3 p.m., ET; and Friday, June 26, 2009,
from 9 a.m. to 11:45 a.m., ET.
ADDRESSES: The Ritz-Carlton,
Washington, DC, 1150 22nd Street, NW.,
Washington, DC 20037. Phone 202–835–
0500.
FOR FURTHER INFORMATION CONTACT: Ms.
Diane M. Gianelli, Director of
Communications, The President’s
Council on Bioethics, 1425 New York
Avenue, NW., Suite C100, Washington,
DC 20005. Telephone: 202/296–4669. Email: info@bioethics.gov. Web site:
https://www.bioethics.gov.
SUPPLEMENTARY INFORMATION: The
meeting agenda will be posted at
https://www.bioethics.gov. The Council
encourages public input, either in
person or in writing. At this meeting,
interested members of the public may
address the Council, beginning at 11:30
a.m., on Friday, June 26. Comments are
limited to no more than five minutes per
speaker or organization. As a courtesy,
please inform Ms. Diane M. Gianelli,
Director of Communications, in advance
of your intention to make a public
statement, and give your name and
affiliation. To submit a written
statement, mail or e-mail it to Ms.
Gianelli at one of her contact addresses
given above.
Dated: May 18, 2009.
F. Daniel Davis,
Executive Director, The President’s Council
on Bioethics.
[FR Doc. E9–12538 Filed 5–28–09; 8:45 am]
BILLING CODE 4154–06–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0215]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Recordkeeping
Requirements for Microbiological
Testing and Corrective Measures for
Bottled Water
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on PROD1PC66 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
VerDate Nov<24>2008
17:24 May 28, 2009
Jkt 217001
publish notice in the Federal Register
concerning each proposed collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the collection of information provisions
of the final rule, ‘‘Beverages: Bottled
Water,’’ published elsewhere in this
issue of the Federal Register, which
requires both domestic and foreign
bottled water manufacturers that sell
bottled water in the United States to
maintain records of Escherichia coli
testing and corrective measures, in
addition to existing recordkeeping
requirements.
DATES: Submit written or electronic
comments on the collection of
information by July 28, 2009.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3794.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Recordkeeping Requirements for
Microbiological Testing and Corrective
Measures for Bottled Water—21 CFR
129.35(a)(3)(i), 129.80(g), and 129.80(h)
FDA has amended its bottled water
regulations in parts 129 and 165 (21
CFR parts 129 and 165) by requiring that
if any coliform organisms are detected
in weekly total coliform testing of
finished bottled water, follow-up testing
must be conducted to determine
whether any of the coliform organisms
are E. coli. FDA also amended the
adulteration provision of the bottled
water standard (§ 165.110(d)) to indicate
that finished product that tests positive
for E. coli will be deemed adulterated
under section 402(a)(3) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
342(a)(3)). In addition, FDA amended
the Current Good Manufacturing
Practices (CGMP) regulations for bottled
water in part 129 by requiring that
source water from other than a public
water system (PWS) be tested at least
weekly for total coliform. If any coliform
organisms are detected in the source
water, the bottled water manufacturers
are required to determine whether any
of the coliform organisms are E. coli.
Source water found to contain E. coli is
not considered water of a safe, sanitary
quality and would be unsuitable for
bottled water production. Before a
bottler may use source water from a
source that has tested positive for E.
coli, a bottler must take appropriate
measures to rectify or otherwise
eliminate the cause of the
contamination. A source previously
found to contain E. coli will be
considered negative for E. coli after five
samples collected over a 24-hour period
from the same sampling site are tested
and found to be E. coli negative.
Description of Respondents: The
respondents to this proposed
information collection are domestic and
foreign bottled water manufacturers that
sell bottled water in the United States.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\29MYN1.SGM
29MYN1
25753
Federal Register / Vol. 74, No. 102 / Friday, May 29, 2009 / Notices
TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
Recordkeepers
21 CFR Section
Annual Frequency
per Recordkeeping
Total Annual
Records
Hours
per Record
Total Hours
§§ 129.35(a)(3)(i) and
129.80(h)
319 (bottlers subject to
source water and finished product testing)
6
1,914
0.08
153
§§ 129.35(a)(3)(i) and
129.80(h)
2.5 (bottlers conducting
secondary testing of
source water)
5
12
0.08
1
§§ 129.35(a)(3)(i) and
129.80(h)
2.5 (bottlers rectifying contamination)
3
0.25
2
§ 129.80(g) and (h)
95 (bottlers testing finished product only)
3
0.08
23
7.5
285
Total Annual Burden
mstockstill on PROD1PC66 with NOTICES
1There
179
are no capital costs or operating costs associated with this collection of information.
The current CGMP regulations already
reflect the time and associated
recordkeeping costs for those bottlers
that are required to conduct
microbiological testing of their source
water, as well as total coliform testing
of their finished bottled water products.
FDA therefore concludes that any
additional burden and costs in
recordkeeping based on the new testing
requirements for source and finished
bottled water are negligible. FDA
estimates that the labor burden of
keeping records of each test is about 5
minutes per test. FDA also requires
follow-up testing of source water and
finished bottled water products for E.
coli when total coliform positives occur.
FDA expects that 319 bottlers that use
sources other than PWSs may find a
total coliform positive sample about 3
times per year in source testing and
about 3 times in finished product
testing, for a total of 153 hours of
recordkeeping. In addition to the 319
bottlers, about 95 bottlers that use PWSs
may find a total coliform positive
sample about 3 times per year in
finished product testing, for a total of 23
hours of recordkeeping. Upon finding a
total coliform positive sample, bottlers
will then have to conduct a follow-up
test for E. coli.
FDA expects that recordkeeping for
the follow-up test for E. coli will also
take about 5 minutes per test. As shown
in table 1 of this document, FDA
expects that 2.5 bottlers per year will
have to carry out the additional E. coli
testing, with a burden of 1 hour. These
bottlers will also have to keep records
about rectifying the source
contamination, for a burden of 2 hours.
For all expected total coliform testing, E.
coli testing, and source rectification,
FDA estimates a total burden of 179
hours. FDA bases its estimate on its
VerDate Nov<24>2008
17:24 May 28, 2009
Jkt 217001
experience with the current CGMP
regulations.
Dated: May 18, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–12493 Filed 5–26–09; 4:15 pm]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10078]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare &
Medicaid Services.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS) is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
1. Type of Information Collection
Request: Extension without change of a
currently approved collection; Title of
Information Collection: Matching Grants
to States for the Operation of High Risk
Pools; Use: CMS is requiring this
information as a condition of eligibility
for grants that were authorized in the
Trade Act of 2002, the Deficit Reduction
Act of 2005 and the State High Risk Pool
Funding Extension Act of 2006. The
information is necessary to determine if
a state applicant meets the necessary
eligibility criteria for a grant as required
by law. The respondents will be States
that have a high risk pool as defined in
sections 2741, 2744, or 2745 of the
Public Health Service Act. The grants
will provide funds to States that incur
losses in the operation of high risk
pools. High risk pools are set up by
States to provide health insurance to
individuals that cannot obtain health
insurance in the private market because
of a history of illness; Form Numbers:
CMS–10078 (OMB#: 0938–0887);
Frequency: Recordkeeping, Reporting—
Occasionally; Affected Public: State,
Local and Tribal Governments; Number
of Respondents: 31; Total Annual
Responses: 31; Total Annual Hours:
1,240. (For policy questions regarding
this collection contact Paul Scholz at
410–786–6178. For all other issues call
410–786–1326.)
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web Site
at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
E:\FR\FM\29MYN1.SGM
29MYN1
Agencies
[Federal Register Volume 74, Number 102 (Friday, May 29, 2009)]
[Notices]
[Pages 25752-25753]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-12493]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0215]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Recordkeeping Requirements for Microbiological Testing
and Corrective Measures for Bottled Water
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on the collection of information provisions of
the final rule, ``Beverages: Bottled Water,'' published elsewhere in
this issue of the Federal Register, which requires both domestic and
foreign bottled water manufacturers that sell bottled water in the
United States to maintain records of Escherichia coli testing and
corrective measures, in addition to existing recordkeeping
requirements.
DATES: Submit written or electronic comments on the collection of
information by July 28, 2009.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Information
Management (HFA-710), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-796-3794.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Recordkeeping Requirements for Microbiological Testing and Corrective
Measures for Bottled Water--21 CFR 129.35(a)(3)(i), 129.80(g), and
129.80(h)
FDA has amended its bottled water regulations in parts 129 and 165
(21 CFR parts 129 and 165) by requiring that if any coliform organisms
are detected in weekly total coliform testing of finished bottled
water, follow-up testing must be conducted to determine whether any of
the coliform organisms are E. coli. FDA also amended the adulteration
provision of the bottled water standard (Sec. 165.110(d)) to indicate
that finished product that tests positive for E. coli will be deemed
adulterated under section 402(a)(3) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 342(a)(3)). In addition, FDA amended the
Current Good Manufacturing Practices (CGMP) regulations for bottled
water in part 129 by requiring that source water from other than a
public water system (PWS) be tested at least weekly for total coliform.
If any coliform organisms are detected in the source water, the bottled
water manufacturers are required to determine whether any of the
coliform organisms are E. coli. Source water found to contain E. coli
is not considered water of a safe, sanitary quality and would be
unsuitable for bottled water production. Before a bottler may use
source water from a source that has tested positive for E. coli, a
bottler must take appropriate measures to rectify or otherwise
eliminate the cause of the contamination. A source previously found to
contain E. coli will be considered negative for E. coli after five
samples collected over a 24-hour period from the same sampling site are
tested and found to be E. coli negative.
Description of Respondents: The respondents to this proposed
information collection are domestic and foreign bottled water
manufacturers that sell bottled water in the United States.
FDA estimates the burden of this collection of information as
follows:
[[Page 25753]]
Table 1.--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual
21 CFR Section Recordkeepers per Recordkeeping Records Hours per Record Total Hours
----------------------------------------------------------------------------------------------------------------
Sec. Sec. 319 (bottlers 6 1,914 0.08 153
129.35(a)(3)(i) subject to
and 129.80(h) source water
and finished
product
testing)
----------------------------------------------------------------------------------------------------------------
Sec. Sec. 2.5 (bottlers 5 12 0.08 1
129.35(a)(3)(i) conducting
and 129.80(h) secondary
testing of
source water)
----------------------------------------------------------------------------------------------------------------
Sec. Sec. 2.5 (bottlers 3 7.5 0.25 2
129.35(a)(3)(i) rectifying
and 129.80(h) contamination)
----------------------------------------------------------------------------------------------------------------
Sec. 129.80(g) 95 (bottlers 3 285 0.08 23
and (h) testing
finished
product only)
----------------------------------------------------------------------------------------------------------------
Total Annual Burden 179
----------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating costs associated with this collection of information.
The current CGMP regulations already reflect the time and
associated recordkeeping costs for those bottlers that are required to
conduct microbiological testing of their source water, as well as total
coliform testing of their finished bottled water products. FDA
therefore concludes that any additional burden and costs in
recordkeeping based on the new testing requirements for source and
finished bottled water are negligible. FDA estimates that the labor
burden of keeping records of each test is about 5 minutes per test. FDA
also requires follow-up testing of source water and finished bottled
water products for E. coli when total coliform positives occur. FDA
expects that 319 bottlers that use sources other than PWSs may find a
total coliform positive sample about 3 times per year in source testing
and about 3 times in finished product testing, for a total of 153 hours
of recordkeeping. In addition to the 319 bottlers, about 95 bottlers
that use PWSs may find a total coliform positive sample about 3 times
per year in finished product testing, for a total of 23 hours of
recordkeeping. Upon finding a total coliform positive sample, bottlers
will then have to conduct a follow-up test for E. coli.
FDA expects that recordkeeping for the follow-up test for E. coli
will also take about 5 minutes per test. As shown in table 1 of this
document, FDA expects that 2.5 bottlers per year will have to carry out
the additional E. coli testing, with a burden of 1 hour. These bottlers
will also have to keep records about rectifying the source
contamination, for a burden of 2 hours. For all expected total coliform
testing, E. coli testing, and source rectification, FDA estimates a
total burden of 179 hours. FDA bases its estimate on its experience
with the current CGMP regulations.
Dated: May 18, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-12493 Filed 5-26-09; 4:15 pm]
BILLING CODE 4160-01-S